Moreover, CAR-T therapy as a broad anti-cancer platform to treat a diverse array of hematologic and solid malignancies is rapidly growing with over 1150 CAR-T cell therapies in development globally in 2021, including 512 ongoing phase I–III human trials targeting numerous antigens for both hematologic (e.g., CD19, BCMA, CD22, CD20, CD123, CD33) and solid malignancies (HER2, PSMA, MSLN, GD2, EGFR, GPC2/3, NYESO1, etc.). This evidence concerns the gene EGFR and cancer.